Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs

This Week: Ketamine Combination Therapy Startup Freedom Biosciences Raises $10m Seed DEA Abandons Plan to Schedule 2 Psychedelics, for Now Analysis: Majority of Oregon Counties Will Send Psilocybin Opt-Out to November Vote, but Maps Can Be Misleading New Study Shows Promise of Psilocybin for Alcohol Use Disorder (more analysis next week) and more… New Study Shows Promise of Psilocybin for Alcohol…

Source